Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasotraline in children with ADHD
NCT03231800Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jul 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Dasotraline with Placebo (2 arms). Primary endpoint: Swanson, Kotkin, Agler, M-Flynn, and Pelham Rating Scale Combined Score at Day 15. Started Jul 2017; status: completed.
02
Drugs
dasotraline
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03231800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03231800.